MedTrace Logo

Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa

NCT02579369 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2023-08-25

No results posted yet for this study

Summary

This is a phase I/II open-label study to evaluate the efficacy and safety of ALLO-ASC-DFU in patients with Dystrophic Epidermolysis Bullosa.

Conditions

  • Dystrophic Epidermolysis Bullosa

Interventions

OTHER

Allogeneic mesenchymal stem cells

Dressing for Dystrophic Epidermolysis Bullosa wound.

DEVICE

Polyurethene Film

Dressing for Dystrophic Epidermolysis Bullosa wound.

Sponsors & Collaborators

  • Anterogen Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Su Chan Kim, PhD. · Gangnam Severence Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
10 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-08
Primary Completion
2016-04-01
Completion
2023-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02579369 on ClinicalTrials.gov